ASH 2020 – Focused on Myelodysplastic Syndromes
High Complete Response Rates With Magrolimab and Azacitidine Plus Venetoclax in Newly Diagnosed, High-Risk...
According to results from a phase I/II study, more than 90% of older and high-risk patients with newly diagnosed acute myeloid leukemia (AML) had...
Polycythemia Vera Patients Have Improved Hematocrit Response With Rusfertide
Treatment with the investigational injectable hepcidin mimetic rusfertide effectively controlled levels of hematocrit and significantly reduced the need for phlebotomy in patients with polycythemia...
Preclinical Model Shows Promise of Magrolimab Plus Venetoclax-Azacitidine in AML
In in vitro and in vivo preclinical models, the combination of magrolimab with venetoclax plus azacitidine increased phagocytosis and prolonged survival in AML cells,...
Mitapivat Produces Durable Hemoglobin Responses in Patients With Pyruvate Kinase Deficiency
Based on analysis of data from the ACTIVATE and ACTIVATE-T studies and their associated long-term extension (LTE) phases, mitapivat (AG-348) appeared to significantly improve...
Recent Hematology and Oncology Headlines
Pandemic Having Major Impact on Pediatric Oncology Providers
The COVID-19 pandemic is having a profound impact on pediatric oncology health care providers (HCPs), according to a study published online Jan. 24 in...
Breast Cancer Survivors Face Higher Risk for Hypertension, Diabetes
Women with, versus without, a history of breast cancer have a higher incidence of hypertension and diabetes up to 10 years following diagnosis, according...
Nomogram May Help Predict Survival in Primary Intestinal NHL
A nomogram can assist clinicians in predicting cancer-specific survival in patients with primary intestinal non-Hodgkin lymphoma, according to a study published online Dec. 20...
Oncology News Round-Up: Amivantamab in Relapsed NSCLC, and More
Each week on DocWire News, editors bring you the latest in oncology news and cancer research. In case you missed it, here are this...